Dr Linda Mellbin, of the Karolinska Institutet in Stockholm, Sweden, said: “There is a need for us to consider cardiovascular risk when choosing type 2 diabetes medications and use treatments with a proven cardiovascular benefit in people who are at high risk. These new analyses further reinforce the cardiovascular benefits of semaglutide in a broad range of people with type 2 diabetes.”
The positive effect of semaglutide on MACE appeared to be consistent across sub-groups of study participants regardless of their kidney function, when compared to those taking a placebo.
HbA1c (blood sugar levels) were also reported as a positive effect of semaglutide in comparison to the placebo.
Florian M. M. Baeres, Corporate Vice President of Novo Nordisk, said: “We believe in the potential and versatility of the semaglutide molecule, which has demonstrated multiple clinical benefits in people living with type 2 diabetes, obesity and cardiovascular disease. Cardiovascular disease remains the leading cause of death worldwide and it is our ambition to provide wider treatment options to reduce the disease burden for people living with cardiovascular disease.”
The results presented were compiled from reports of the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials, which included a total of 6,480 adults with type 2 diabetes at high cardiovascular risk.
The SUSTAIN 6 and PIONEER 6 studies assessed the effect of Ozempic and Rybelsus, respectively, on the risk of MACE (death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke) compared with placebo treatment.
Find out more about type 2 diabetes
Support DRWF by making a donation here
Find out more about DRWF-funded research here
Find out more about DRWF fundraising here
To receive the charity’s latest bulletins as they become available, please sign up here
Read DRWF diabetes information leaflets here
Join the Diabetes Wellness Network here
I would like to make a regular donation of
I would like to make a single donation of